These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23432617)

  • 1. Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
    Gruson B; Lortholary O; Canioni D; Chandesris O; Lanternier F; Bruneau J; Grosbois B; Livideanu C; Larroche C; Durieu I; Barete S; Sevestre H; Diouf M; Chaby G; Marolleau JP; Dubreuil P; Hermine O; Damaj G
    Br J Haematol; 2013 May; 161(3):434-42. PubMed ID: 23432617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide in advanced mastocytosis.
    Damaj G; Bernit E; Ghez D; Claisse JF; Schleinitz N; Harlé JR; Canioni D; Hermine O
    Br J Haematol; 2008 Apr; 141(2):249-53. PubMed ID: 18307561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.
    Simon J; Lortholary O; Caillat-Vigneron N; Raphaël M; Martin A; Brière J; Barète S; Hermine O; Casassus P;
    Pathol Biol (Paris); 2004 Jun; 52(5):294-9. PubMed ID: 15217717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions.
    Jennings S; Russell N; Jennings B; Slee V; Sterling L; Castells M; Valent P; Akin C
    J Allergy Clin Immunol Pract; 2014; 2(1):70-6. PubMed ID: 24565772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic mastocytosis with diffuse cutaneous involvement and haematological disease presenting in utero treated unsuccessfully with vincristine.
    Angus J; Leach IH; Grant J; Ravenscroft JC
    Clin Exp Dermatol; 2008 Jan; 33(1):36-9. PubMed ID: 17983456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
    Paul C; Sans B; Suarez F; Casassus P; Barete S; Lanternier F; Grandpeix-Guyodo C; Dubreuil P; Palmérini F; Mansfield CD; Gineste P; Moussy A; Hermine O; Lortholary O
    Am J Hematol; 2010 Dec; 85(12):921-5. PubMed ID: 21108325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New views on systemic mastocytosis].
    Pluta A; Gutkowski K
    Pol Merkur Lekarski; 2003 Feb; 14(80):159-62. PubMed ID: 12728681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current approaches to the diagnosis and treatment of systemic mastocytosis.
    Bains SN; Hsieh FH
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):1-10; quiz 10-2, 41. PubMed ID: 20143640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
    Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
    J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
    Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
    Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study.
    Pardanani A; Baek JY; Li CY; Butterfield JH; Tefferi A
    Mayo Clin Proc; 2002 Nov; 77(11):1169-75. PubMed ID: 12440552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient with skin lesions, osteosclerosis and hepatosplenomegaly.
    Ustun C; Cayci Z; Courville E
    Br J Haematol; 2014 Nov; 167(3):291. PubMed ID: 25039362
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2010; 77(4):169-80. PubMed ID: 20616612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered apoptosis and cell cycling of mast cells in bone marrow lesions of patients with systemic mastocytosis.
    Baldus SE; Zirbes TK; Thiele J; Eming SA; Henz BM; Hartmann K
    Haematologica; 2004 Dec; 89(12):1525-7. PubMed ID: 15590405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indolent systemic mastocytosis: a case and review of the current available treatment options.
    Lee Y; Wood P; Soyer HP
    Dermatol Online J; 2013 Jun; 19(6):18562. PubMed ID: 24011312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: study of five cases.
    Brazzelli V; Grasso V; Manna G; Barbaccia V; Merante S; Boveri E; Borroni G
    J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):465-9. PubMed ID: 21564325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
    Alvarez-Twose I; González-de-Olano D; Sánchez-Muñoz L; Matito A; Jara-Acevedo M; Teodosio C; García-Montero A; Morgado JM; Orfao A; Escribano L
    Int Arch Allergy Immunol; 2012; 157(3):275-80. PubMed ID: 22042301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous mastocytosis in adults. evaluation of 14 patients with respect to systemic disease manifestations.
    Tebbe B; Stavropoulos PG; Krasagakis K; Orfanos CE
    Dermatology; 1998; 197(2):101-8. PubMed ID: 9732155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.